Current Edition

ERT Expands Respiratory Services to Support New Endpoints

Industry-leading MasterScope™ integrates with centralized Forced Oscillation Technique service to deliver high quality data while lessening patient and site burden
 ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced an advanced respiratory clinical trial service that centrally collects lung function data using the Forced Oscillation Technique (FOT). The service is available immediately for trials of asthma, COPD and other respiratory conditions.
Used in combination with FEV1 and other protocol endpoints, FOT enables trial sponsors to monitor airway resistance, reactance and other lung function parameters by assessing small airways, where changes can be detected earlier than with spirometry and imaging assessments. Since it only requires patients to breathe normally into a mouthpiece with minimal instruction, FOT reduces patient and investigative site burden and overcomes the challenges associated with performing proper spirometry maneuvers, especially in elderly and pediatric patients.
The centralized FOT service delivers easy to use, efficient FOT measurement via Thorasys’ tremoflo® device and ERT’s industry-leading MasterScopeTM spirometry platform. Through integration with tremoflo, MasterScope provides clear workflow management and patient guidance with real-time signal displays, all of which improve protocol compliance and data quality.
“We’re pleased to offer this centralized FOT service and look forward to rapidly expanding it to support additional devices our customers are using in their clinical research,” said Achim Schülke, Executive Vice President, Respiratory Solutions at ERT. “We are committed to continuing ERT’s rich heritage of innovative respiratory solutions that help trial sponsors meet their development objectives while maintaining regulatory compliance so they can move ahead quickly, and with confidence.”